The MHRA has given Nuformix approval to commence human pharmacokinetics studies with NXP001 to further assess its potential for chemotherapy-induced nausea and vomiting.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.